<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.4-a.1'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//pepslatam.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://pepslatam.com/2026/10/20/cagrisema-cagrilintida-semaglutida-estudios-2026/</loc>
  <lastmod>2026-10-20T10:57:25Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>PepsLatam</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>CagriSema: qué mostraron los estudios de 2026 sobre la combinación de amilina y semaglutida</news:title>
   <news:publication_date>2026-10-20T10:57:17Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pepslatam.com/2026/10/19/tirzepatida-perdida-musculo-composicion-corporal/</loc>
  <lastmod>2026-10-19T10:58:03Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>PepsLatam</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Tirzepatida y pérdida de músculo: qué muestran los estudios de 2026</news:title>
   <news:publication_date>2026-10-19T10:58:03Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pepslatam.com/calculadora/</loc>
  <lastmod>2026-10-19T12:32:40Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>PepsLatam</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Calculadora de reconstitución de péptidos</news:title>
   <news:publication_date>2026-10-18T23:15:33Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://pepslatam.com/2026/10/18/mots-c-ensayo-humanos-fda-2026/</loc>
  <lastmod>2026-10-18T10:57:09Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>PepsLatam</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>MOTS-c: el péptido mitocondrial que llegó a ensayos en humanos y a la FDA en 2026</news:title>
   <news:publication_date>2026-10-18T10:57:09Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
